High-income countries are moving toward tuberculosis (TB) elimination. Sophisticated diagnostic tests and effective treatment regimens are readily available. The range of available resources even makes effective treatment of multidrug-resistant tuberculosis (MDRTB) possible. The introduction of highly active antiretroviral therapy and specific TB control measures has reduced the incidence of HIV-associated TB disease. Unfortunately, the situation in low-income countries that carry 95% of the global TB burden is less positive. TB diagnosis still relies upon sputum smear microscopy. The management of MDRTB remains problematic though guidelines for DOTS-plus programs have been developed, and cheaper second-line drugs are becoming available. The HIV epidemic continues to confound TB control efforts, particularly in sub-Saharan Africa. The appropriate package of interventions for controlling HIV/TB disease remains undefined and unimplemented. The international community must provide the funding and technical support to address the alarming dichotomy in TB control that exists between rich and poor countries. Tuberculosis (TB) has been called the perfect expression of an imperfect civilization [1] . A review of the medical literature on TB management published during the last 12 months confirms this quotation. Low-income countries that bear 95% of the global TB burden and have only minimal resources are confronting major problems with TB control, HIV/TB co-infection, and multidrug-resistant TB (MDRTB) [2] . Meanwhile, the highincome countries that carry 5% of the global TB burden have used their considerable capabilities to address these same problems and are now planning for TB elimination. This review will highlight this dichotomy while summarizing recent publications on the management (ie, investigation and treatment) of TB in individual patients, in specific patient subgroups (eg, MDRTB patients), and at the population level.
Innovations in TB diagnostics
The dichotomy between high-and low-income countries is most obvious when considering the field of TB diagnostics. High-income countries have a plethora of expensive intricate diagnostic tests to detect an increasingly small number of TB patients. The BACTEC radiometric culture system is being replaced by nonradiometric culture methods of equal speed and performance for the detection and susceptibility of Mycobacterium tuberculosis [3] . These culture methods are being supplemented by numerous molecular methods that further speed diagnoses. For example, El-Hajj et al.
[4] described a singletube polymerase chain reaction (PCR) assay, employing five probes targeting the rpoB gene and labeled with different fluorophores that can identify rifampicinresistant M. tuberculosis directly from sputum within 3 hours.
In contrast, accurate case detection remains the weak link in the World Health Organization (WHO) directly observed therapy-short course (DOTS) strategy in lowincome countries [5] . Sputum microscopy, which is the only diagnostic test widely available in these settings, is insensitive, labor-intensive, tends to detect advanced rather than early disease, and is inadequate for detecting many HIV/TB cases as well as pediatric and extrapulmonary disease. New culture and molecular methods are too expensive and complex for routine use in lowincome countries. Despite improvements in the range and quality of antigens, serological tests continue to be confounded by limited sensitivity and/or specificity. For example, the sensitivity and specificity of a rapid 
Innovations in TB treatment
The principles that guide the design of appropriate anti-TB regimens effecting high cure rates (95-98%) and limiting the risks of acquired drug resistance and disease relapse remain unchanged. Namely, the use of two to three agents to which the organism is fully susceptible, a treatment period of sufficient duration, and never adding a single drug to a failing regimen. Given treatment is reliant on the same few effective agents, careful application of these basic rules remains crucial and implementation of treatment (daily or intermittent) must be backed by careful patient supervision.
Newer agents that are at least as effective as the "antiquated" mainstays of treatment, isoniazid and rifampicin, and that allow for less frequent dosing and/or a shorter treatment period are desperately needed. Although research in TB drug development has intensified since the early 1990s, the target date for a substantial advance in TB chemotherapy is still 2010 [8].
Fixed-dose combinations
The advent of TB drugs in fixed-dose combination (FDC) offers the advantage of making treatment delivery less complex and also may prevent acquired drug resistance [9] . Ensuring bioavailability of each component in the FDC, particularly that of rifampicin, remains the major concern. Evidence suggests that such combination agents are comparable with separate formulations at the same dose [10]. WHO supports the use of FDC only on a daily basis and if an accredited laboratory confirms quality control requirements.
Shorter or less frequent treatment
Reducing the standard 6-month regimen to 4 months (ie, isoniazid and rifampicin throughout with pyrazinamide for the first 2 months only) has only been shown to be effective in smear-and culture-negative patients who are not immune-suppressed, have limited pulmonary disease, and have little likelihood of drug resistance [11] . Hence, in many high-risk settings, this abridged treatment would not be satisfactory. Furthermore, studies of culture-negative disease have inherent problems: risk of over-diagnosis and inclusion of inactive TB disease or non-TB disorders. All of these biases tend to overstate the benefit of the 4-month regimen.
The patient and the treatment service would benefit from an agent that allows for less frequent dosing. Rifapentine, a semisynthetic derivative of rifampicin with a significantly longer serum half-life, has been the subject of clinical trials. Recent reports on studies of HIVnegative subjects utilizing once weekly rifapentine and isoniazid compared with twice weekly rifampicin and isoniazid only in the continuation phase of treatment offer the prospect of some simplification of treatment [12,13•]. Overall the Hong Kong and CDC studies showed that the once weekly rifapentine 600 mg/isoniazid 900 mg regimen resulted in relapse rates significantly higher than the standard twice-weekly rifampicin-based regimen [12,13•]. However, the results of the CDC study suggested that the difference in outcome is less significant if the rifapentine regimen is restricted to those with non-cavitary and less-extensive pulmonary disease and in whom sputum cultures at the end of the 2-month intensive phase are negative [13•].
A suboptimal dose of rifapentine due to the drug's higher protein binding is one explanation for these inferior results. Hence, an increased dose may be more effective.
Another CDC study to consider safety as a prelude to phase III efficacy studies demonstrated that higher doses (900 mg and 1,200 mg) were tolerated [14].
The above-mentioned studies disagreed as to the impact of the lower weekly dose of isoniazid in the rifapentine study groups. The detection of acquired resistance to rifampicin in advanced HIV-positive cases after the use of an intermittent regimen in the continuation phase suggests that the once weekly isoniazid dose may be too low [12, 15] . Once weekly rifapentine is ill-advised in this high-risk subset of patients.
New agents
The use of fluoroquinolones has been limited to the treatment of MDRTB. The use of murine models to assess the newer agents, moxifloxacin and gatifloxacin, have shown promise for wider fluoroquinolone use. A recent study involving mice found that the addition of moxifloxacin, both in the initial daily phase (2 weeks, combined with isoniazid, rifampicin, and pyrazinamide) and also the once weekly continuation phase (5.5 months, with rifapentine and isoniazid) was almost as effective as the standard short-course regimen [16] .
The results inferred a pronounced sterilizing effect from the addition of moxifloxacin in the continuation phase and hence present a potential alternative to isoniazid, which has limited sterilizing activity.
In a separate murine-model study [17] , the activity after 12 weeks of gatifloxacin in combination with ethionamide, ethambutol, and pyrazinamide compared favorably with that of isoniazid and rifampicin with or without gatifloxacin. From their overall results, the investigators suggested that the combination of gatifloxacin, ethionamide, and pyrazinamide with or without ethambutol would likely benefit MDTRB treatment. The benefit of gatifloxacin used in a higher dose needs further evaluation.
Potential new agents
A nitroimidazopyran compound, PA824, has been the subject of recent interest because of demonstrated bactericidal activity comparable to isoniazid in a mouse model [8] . The other interesting feature of this new agent was activity against nonreplicating bacilli suggesting possible potential for shortening TB treatment as well for treatment of latent infection. Meanwhile, TB control programs in low-income countries and their international advisers are still contemplating the advantages and disadvantages of instituting MDRTB treatment (ie, so-called DOTS-plus initiatives). However, there has been some important new information in the last 12 months that will guide this decisionmaking process. Schaaf et al.
Management of patients with MDTRB
[21] followed 119 South African children exposed to MDRTB and found that the incidence of infection and disease was comparable with that occurring in contacts of drug-susceptible index cases. Dye et al.
[22•] have also modeled the spread of MDRTB following the introduction of combination chemotherapy and estimated that the relative reproductive fitness of MDRTB strains is comparable to but "at the lower end of the range" of drug-susceptible strains (ie, f ≈ 0.3). Localized areas with high prevalences of MDRTB are therefore most likely due to poor treatment programs rather than local transmission of a MDRTB superbug. These modeling studies confirm that TB control programs should continue to concentrate on effective management of drug-susceptible disease using the DOTS strategy.
However, models also suggest that MDRTB incidence in the "hot spots" will be reduced more rapidly by ef- 
HIV and TB
The dichotomy between affluent and poor countries is also evident when considering the co-epidemics of HIV Pharmaceutical companies and the international community must continue striving for equitable access to HAART. Health delivery systems within the lowincome countries must also be developed to deliver HAART safely and securely [33•]. TB and AIDS control programs will need to work cooperatively to achieve this goal.
DOTS strategy
The WHO strategy, well known as DOTS, has become the programmatic benchmark and remains the backbone of efforts to control TB, particularly in resource-poor settings [38] . Although DOTS appears to have improved TB control in many areas, the strategy's relatively slow uptake and tardy progression towards the global targets of 70% case detection and 85% cure rate have led to the Global Stop TB partnership, the Global Drug Facility, and Global DOTS Expansion Plan [39]. These initiatives reflect an attempt to expand TB control efforts and harness additional resources (financial and human) through promoting partnerships between government and nongovernment organizations and public and private sectors.
The directly observed therapy (DOT) element of DOTS has been strongly advocated as best practice for treatment of the individual. The consensus appears to be that DOT improves overall treatment outcomes but this has yet to be established at the evidence-based level 
TB management issues in low-incidence high-income countries
The Another problem confronting TB control in lowincidence countries is that the current generation of medical staff is unfamiliar with TB and is confronted with fewer cases. This unfamiliarity with pulmonary TB disease leads to diagnostic delay, greater patient morbidity and mortality, and nosocomial transmission of TB [49] . Interestingly, the increased use of fluoroquinolones for the treatment of community-acquired pneumonia (CAP) may be another factor delaying TB diagnosis in high-income low-incidence countries. Dooley et al. [50] reported that almost one-half of their cohort of new pulmonary TB patients had received a fluoroquinolone for presumed CAP, had improved symptomatically because of the drug's anti-TB activity, and subsequently had a significantly delayed institution of appropriate anti-TB treatment.
Nonspecific presentations of extrapulmonary TB disease make prompt diagnosis and treatment even more problematic in low-incidence countries. For example, TB peritonitis can be easily confused with spontaneous bacterial peritonitis in certain patients and the diagnosis will not be made unless the appropriate investigation (ie, mycobacterial culture of a peritoneal biopsy) is ordered [51] . Doctors in high-income countries are also being required to prevent, diagnose, and treat TB in special patient groups (eg, immunosuppressed transplant recipients and patients with chronic renal failure) where a high index of suspicion is required to make the diagnosis and treatment may be confounded by adverse drug reactions [52] [53] [54] .
Treatment of LTBI
Cost-effective treatment of LTBI is of particular importance for TB control programs in high-income lowincidence countries. Treatment choice has until recently centered on the use of isoniazid, unless isoniazid resistance is strongly suspected. Although daily monotherapy for a minimum of 6 months has been generally accepted, 9 months is preferred and certainly advised in children and the HIV-infected. Intermittent use on a supervised basis is probably equally effective [55] .
The recent ATS/CDC recommendations have also been expanded to support use of the 2-month rifampicin/pyrazinamide regimen in HIV-positive persons based on demonstrated efficacy and safety [55] . Concerns over the use of this regimen in the HIVnegative person were raised after reports of associated serious hepatotoxicity and death [56] . Revisions have therefore been made accepting its use but providing no other hepatotoxic agent is regularly used and there is no underlying liver damage. Cautious (but contentious) regular fortnightly monitoring has been firmly advocated.
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